Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
WuXi AppTec H | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$160.72B | 18.9x | -1.24 | HK$56.60 | 1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 11.1% Upside | Upgrade to Pro+ | |
Hansoh Pharmaceutical Group | Hong Kong | Healthcare | Pharmaceuticals | HK$100.77B | 25.7x | 0.27 | HK$17.02 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 35.2% Upside | Upgrade to Pro+ | |
WuXi Biologics | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$76.61B | 22.9x | -0.71 | HK$19.04 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8.5% Upside | Upgrade to Pro+ | |
Sinopharm Group Co | Hong Kong | Healthcare | Pharmaceuticals | HK$62.23B | 6.8x | -2.23 | HK$20.15 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22% Upside | Upgrade to Pro+ | |
Akeso | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$53.67B | -74.9x | 0.5 | HK$60.45 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.1% Upside | Upgrade to Pro+ | |
Sino Biopharmaceutical | Hong Kong | Healthcare | Pharmaceuticals | HK$52.37B | 12.2x | 0.18 | HK$2.91 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 49.6% Upside | Upgrade to Pro+ | |
Innovent Biologics | Hong Kong | Healthcare | Pharmaceuticals | HK$50.86B | -36.6x | -3.47 | HK$31.20 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
CSPC Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$50.73B | 9.6x | -0.61 | HK$4.44 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Pharmaron Beijing Co Ltd | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$48.03B | 24.1x | 1.02 | HK$14.06 | 1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 35.4% Upside | Upgrade to Pro+ | |
Tigermed | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$46.39B | 45.6x | -0.72 | HK$29.30 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 36.3% Upside | Upgrade to Pro+ | |
Shanghai Pharma Holding | Hong Kong | Healthcare | Pharmaceuticals | HK$45.16B | 10.6x | -1.39 | HK$12.26 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20.5% Upside | Upgrade to Pro+ | |
Sichuan Kelun Biotech | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$37.37B | -188x | -2.68 | HK$167.10 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 35.5% Upside | Upgrade to Pro+ | |
WuXi XDC Cayman | Hong Kong | Healthcare | Pharmaceuticals | HK$36.25B | 48.1x | 0.46 | HK$30.65 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.5% Upside | Upgrade to Pro+ | |
Shanghai Fosun Pharmaceutical | Hong Kong | Healthcare | Pharmaceuticals | HK$35.19B | 15.9x | -0.65 | HK$13.44 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 30.2% Upside | Upgrade to Pro+ | |
China Resources Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$32.23B | 8x | 0.79 | HK$5.15 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 35.9% Upside | Upgrade to Pro+ | |
Asymchem Laboratories Tianjin | Hong Kong | Healthcare | Pharmaceuticals | HK$28.51B | 35x | -0.46 | HK$49.70 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 48.1% Upside | Upgrade to Pro+ | |
Guangzhou Baiyunshan Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$28.16B | 7.7x | -0.61 | HK$17.36 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 21.9% Upside | Upgrade to Pro+ | |
Livzon Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$23.29B | 16.6x | 7.76 | HK$25.75 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16.7% Upside | Upgrade to Pro+ | |
Zai Lab | Hong Kong | Healthcare | Pharmaceuticals | HK$21.92B | -9.4x | -0.94 | HK$20.80 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genscript Biotech Corp | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$21.27B | -15.3x | -3.12 | HK$10.04 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Shandong Weigao Medical Polymer | Hong Kong | Healthcare | Healthcare Equipment & Supplies | HK$20.48B | 10x | -0.46 | HK$4.57 | 2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 39.9% Upside | Upgrade to Pro+ | |
United Laboratories Int | Hong Kong | Healthcare | Pharmaceuticals | HK$20.21B | 6.6x | 0.22 | HK$11.16 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 7% Upside | Upgrade to Pro+ | |
HUTCHMED | Hong Kong | Healthcare | Pharmaceuticals | HK$19.09B | -57x | 6.54 | HK$21.85 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
China Medical System | Hong Kong | Healthcare | Pharmaceuticals | HK$17.35B | 11.9x | -0.19 | HK$7.21 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 41.4% Upside | Upgrade to Pro+ | |
Simcere | Hong Kong | Healthcare | Pharmaceuticals | HK$16.72B | -14.4x | 0.1 | HK$6.77 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 31.2% Upside | Upgrade to Pro+ | |
Shenzhen Hepalink | Hong Kong | Healthcare | Pharmaceuticals | HK$16.04B | -102.8x | 0.55 | HK$3.82 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 0.8% Upside | Upgrade to Pro+ | |
XtalPi Holdings | Hong Kong | Healthcare | Healthcare Equipment & Supplies | HK$15.43B | -2.6x | HK$4.59 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
China Grand Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$15.27B | 6.4x | 3.26 | HK$4.38 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 42.2% Upside | Upgrade to Pro+ | |
3SBio | Hong Kong | Healthcare | Pharmaceuticals | HK$15B | 8.8x | -0.78 | HK$6.40 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 23.5% Upside | Upgrade to Pro+ | |
Beigene | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$13.60B | -0.3x | -1.67 | HK$128.60 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 37.3% Upside | Upgrade to Pro+ |